rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Utah Medical Products, Inc.

UTMD · Nasdaq

Health CareMedical DevicesLeading

UTMD stood above a rising 150-day average in 43 of the last 52 weekly readings, including each of the last 41 weeks. It is 8.1% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
41 in a row
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
108 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 43 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders108-4 on the quarter
New · exited9 · 12
Reported value$157.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BRANDES INVESTMENT PARTNERS, LPadded · filed 14 Aug 2026475,158$32.8M+25,879+5.8%
BlackRock, Inc.added · filed 7 Aug 2026203,690$14.1M+16,041+8.5%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026198,817$13.7M+909+0.5%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026175,814$12.1M-8,300−4.5%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026134,535$9.3M-4,025−2.9%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026108,048$7.5M-12,049−10.0%
Minerva Advisors LLCunchanged · filed 12 Aug 202693,615$6.5M00.0%
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 202685,231$5.9M-3,900−4.4%
RICE HALL JAMES & ASSOCIATES, LLCadded · filed 7 Aug 202671,363$4.9M+3,481+5.1%
MORGAN STANLEYadded · filed 13 Aug 202669,671$4.8M+20,870+42.8%
31 Mar 2023 – 30 Jun 2026
6990110Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Paul O. Richins Company insiderDirector · last 29 Jun 20260 · 11
Brian Koopman Company insiderPrincipal Financial Officer · last 28 May 20260 · 1
Barbara A. Payne Company insiderDirector · last 8 Feb 20230 · 26
Ernst G. Hoyer Company insiderDirector · last 24 Nov 20210 · 44
Kevin L. Cornwell Company insiderChairman, CEO, Secretary · last 22 Nov 20213 · 71
James H. Beeson Company insiderDirector · last 3 Feb 20173 · 0
Greg A. Leclaire Company insiderChief Financial Officer · last 28 Mar 20060 · 0
Stephen W. Bennett Company insiderDirector · last 31 Jan 20060 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202513.7%
Operating profit marginFY 2025 · to 31 Dec 202529.6%
Free cash flow marginFY 2025 · to 31 Dec 202537.2%
Return on capital employedFY 2025 · to 31 Dec 20259.5%
Research spendFY 2025 · to 31 Dec 20251.7%
Revenue growthFY 2025 · to 31 Dec 2025293%
Earnings per share growthFY 2025 · to 31 Dec 2025324%
Share count trendFY 2025 · to 26 Mar 2026-0.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$85.8M
Free cash flowFY 2025 · to 31 Dec 2025$14.3M

Analyst forecasts

No analyst forecasts yet.